These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15830727)

  • 1. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
    Langguth P; Hanafy A; Frenzel D; Grenier P; Nhamias A; Ohlig T; Vergnault G; Spahn-Langguth H
    Drug Dev Ind Pharm; 2005 Mar; 31(3):319-29. PubMed ID: 15830727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
    Kaukonen AM; Lennernäs H; Mannermaa JP
    J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers.
    Xu FG; Zhang ZJ; Dong HJ; Tian Y; Liu Y; Chen Y
    Arzneimittelforschung; 2008; 58(3):117-21. PubMed ID: 18488807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoamorphous drug products - Design and development.
    Jog R; Burgess DJ
    Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.
    Hanafy A; Spahn-Langguth H; Vergnault G; Grenier P; Tubic Grozdanis M; Lenhardt T; Langguth P
    Adv Drug Deliv Rev; 2007 Jul; 59(6):419-26. PubMed ID: 17566595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation.
    Dong Y; Ng WK; Shen S; Kim S; Tan RB
    Int J Pharm; 2009 Jun; 375(1-2):84-8. PubMed ID: 19481693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro and in-vivo study of amorphous spironolactone prepared by adsorption method using supercritical CO2.
    Jiang Q; Li Y; Fu Q; Geng Y; Zhao J; Ma P; Zhang T
    Drug Dev Ind Pharm; 2015 Feb; 41(2):201-6. PubMed ID: 24369091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing comparative bioavailability of spironolactone tablets.
    Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
    J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of an orodispersible film containing drug nanoparticles.
    Shen BD; Shen CY; Yuan XD; Bai JX; Lv QY; Xu H; Dai L; Yu C; Han J; Yuan HL
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1348-56. PubMed ID: 24103635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in vitro and in vivo evaluation.
    Ramasahayam B; Eedara BB; Kandadi P; Jukanti R; Bandari S
    Drug Dev Ind Pharm; 2015 May; 41(5):753-63. PubMed ID: 24641324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone nanocrystals for oral administration: Different pharmacokinetic performances induced by stabilizers.
    Mu S; Li M; Guo M; Yang W; Wang Y; Li J; Fu Q; He Z
    Colloids Surf B Biointerfaces; 2016 Nov; 147():73-80. PubMed ID: 27490456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method.
    Wang Y; Han X; Wang J; Wang Y
    Int J Pharm; 2016 May; 505(1-2):35-41. PubMed ID: 27034003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
    Abosehmah-Albidy AZ; York P; Wong V; Losowsky MS; Chrystyn H
    Br J Clin Pharmacol; 1997 Jul; 44(1):35-9. PubMed ID: 9241094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.